In­vestors give ail­ing Unum a lease on life and a whole new suite of ex­per­i­men­tal can­cer drugs

In­vestors, it seems, are will­ing to give Unum Ther­a­peu­tics one last shot — or at least one last shot to a com­pa­ny of that name.

The ail­ing can­cer biotech, be­set by a se­ries of clin­i­cal holds and mul­ti­ple failed lead pro­grams, an­nounced to­day that they’ve ac­quired Kiq LLC and that in­vestors are putting in $104 mil­lion to ad­vance Kiq’s pipeline of ki­nase in­hibitors. Unum share­hold­ers will now own on­ly 16.2% of the com­pa­ny and CEO Chuck Wil­son in­di­cat­ed that the cell ther­a­pies the biotech has worked on since its found­ing may be on their way out, say­ing Unum will “ex­plore strate­gic op­tions” for those prod­ucts.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER